Brief: Adamis Pharmaceuticals Doses First Patients In Mid-Stage Trial Of COVID-19 Treatment
02/09/2021 12:35
Sept 2 (Reuters) - Adamis Pharmaceuticals Corp ADMP.O :
* ADAMIS PHARMACEUTICALS DOSES FIRST PATIENTS IN PHASE 2/3
CLINICAL TRIAL FOR TEMPOL IN TREATMENT OF COVID-19
* ADAMIS PHARMACEUTICALS CORP - TRIAL IS DESIGNED TO ENROLL
248
PATIENTS
Source text for Eikon: ID:nGNX1SX2gW
Further company coverage: ADMP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DMK Pharmaceuticals
See all newsBrief: Dmk Pharmaceuticals Corp Says Ebrahim Versi Resigned As Chairman
Brief: ZMI Pharma Finalized Acquisition Of All Strategic Assets Necessary To Manufacture Zimhi From Dmk Pharma
Brief: DMK Pharmaceuticals Files For Chapter 11 Bankruptcy In The U.S. - Court Filing
Brief: Dmk Pharmaceuticals Regains Full Rights To Commercialize Zimhi
Brief: DMK Pharmaceuticals Regains Full Rights From US Worldmeds For Symjepi And Provides Corporate Update